Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669639 | 1.00 | CNR2 (0.34) | CNR2SLC18A3ESR2CYP1A2TSHR | |
| SCHEMBL4814734 | 0.92 | SIGMAR1 (0.33) | CNR2SLC18A3ESR2CYP1A2TSHR | |
| SCHEMBL1543625 | 0.89 | CYP1A2 (0.38) | SLC18A3ESR2CYP1A2TSHRLMNA | |
| SCHEMBL79852 | 0.89 | — | — | |
| SCHEMBL796462 | 0.86 | SLC18A3 (0.40) | SLC18A3CYP1A2TSHRLMNAMAPK1 | |
| SCHEMBL7068277 | 0.86 | SIGMAR1 (0.39) | SLC18A3CYP1A2TSHRLMNAMAPK1 | |
| SCHEMBL25025914 | 0.83 | ESR2 (0.43) | ESR2TSHRSHBG | |
| SCHEMBL18421585 | 0.83 | ESR2 (0.43) | SLC18A3ESR2CYP1A2LMNAMAPK1 | |
| SCHEMBL103167 | 0.83 | ESR2 (0.43) | ESR2TSHRSHBG | |
| SCHEMBL18421980 | 0.83 | SIGMAR1 (0.37) | ESR2CYP1A2TSHRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009110971-A2 | PROCESS FOR CONVERTING MULTIFUNCTIONAL ALIPHATIC ALCOHOLS | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-10723876-B2 | Thermoplastic resin composition and molded article comprising the same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10364348-B2 | Thermoplastic resin composition and molded article comprising the same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2019-07-30 | — | — | US | disclosed |
| EP-3135728-B1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING THE SAME | LOTTE ADVANCED MAT CO LTD (KR) | 2018-03-07 | — | — | EP | disclosed |
| US-20170058122-A1 | Thermoplastic Resin Composition and Molded Article Comprising the Same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
| US-20170058121-A1 | Thermoplastic Resin Composition and Molded Article Comprising the Same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
| EP-3135728-A1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE COMPRISING THE SAME | Lotte Advanced Materials Co., Ltd. (KR) | 2017-03-01 | — | — | EP | disclosed |
| US-20170029617-A1 | Thermoplastic Resin Composition and Molded Article Comprising the Same | LOTTE ADVANCED MATERIALS CO., LTD. (KR) | 2017-02-02 | — | — | US | disclosed |
| US-9522864-B2 | Process for direct conversion of biomass to liquid fuels and chemicals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522864-B2 | Process for direct conversion of biomass to liquid fuels and chemicals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-20 | — | — | US | disclosed |
| US-8796494-B2 | Process for direct conversion of biomass to liquid fuels and chemicals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796494-B2 | Process for direct conversion of biomass to liquid fuels and chemicals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2408465-A2 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | The Johns Hopkins University (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110065814-A1 | PROCESS FOR DIRECT CONVERSION OF BIOMASS TO LIQUID FUELS AND CHEMICALS | NATIONAL SCIENCE FOUNDATION | 2011-03-17 | — | — | US | disclosed |
| US-20110065814-A1 | PROCESS FOR DIRECT CONVERSION OF BIOMASS TO LIQUID FUELS AND CHEMICALS | NATIONAL SCIENCE FOUNDATION | 2011-03-17 | — | — | US | disclosed |
| WO-2010107909-A2 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2009158499-A2 | PREVENTION OF BACTERIAL GROWTH AND BIOFILM FORMATION BY LIGANDS THAT ACT ON CANNABINOIDERGIC SYSTEMS | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | KLK3, KLK2, KLK5 | CNR2 850/4885SLC18A3 3678/4885ESR2 515/4885 |
| US-20110065814-A1 | PROCESS FOR DIRECT CONVERSION OF BIOMASS TO LIQUID FUELS AND CHEMICALS | C9, C5, ADH1C | CNR2 500/4885SLC18A3 3311/4885ESR2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.